Soluble B-cell maturation antigen in multiple myeloma Review
| Authors: | Costa, B. A.; Ortiz, R. J.; Lesokhin, A. M.; Richter, J. |
| Review Title: | Soluble B-cell maturation antigen in multiple myeloma |
| Abstract: | B-cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma-secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme-linked immunosorbent assays, as well as through mass spectrometry-based proteomics. Besides its short serum half-life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti-myeloma therapies. In short, sBCMA might be the “Swiss army knife” of MM laboratory testing, but is it ready for prime time?. © 2024 Wiley Periodicals LLC. |
| Keywords: | protein expression; lenalidomide; cancer recurrence; neurotoxicity; mass spectrometry; protein blood level; cancer immunotherapy; multiple cycle treatment; multiple myeloma; pathology; proteomics; enzyme linked immunosorbent assay; diagnostic value; quantitative analysis; drug response; methylprednisolone; drug half life; fluorescence analysis; adoptive immunotherapy; immunotherapy, adoptive; amyloid precursor protein secretases; secretase; cytokine release syndrome; liquid chromatography-mass spectrometry; antibodies, bispecific; cancer prognosis; bispecific antibody; ruxolitinib; smoldering multiple myeloma; humans; human; article; b cell maturation antigen; monoclonal gammopathy of undetermined significance; antibody drug conjugate; b-cell maturation antigen; chimeric antigen receptor t-cell immunotherapy; sandwich elisa; belantamab mafodotin; ciltacabtagene autoleucel; elranatamab; teclistamab; idecabtagene vicleucel; forimtamig; linvoseltamab; orvacabtagene autoleucel; talquetamab; electrochemiluminescence immunoassay |
| Journal Title: | American Journal of Hematology |
| Volume: | 99 |
| Issue: | 4 |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2024-04-01 |
| Start Page: | 727 |
| End Page: | 738 |
| Language: | English |
| DOI: | 10.1002/ajh.27225 |
| PUBMED: | 38270277 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work